Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Owen-Barry Pharmaceuticals Inc. is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This singular focus suggests a targeted approach to its current intellectual property development. The company's activity is concentrated on a specific innovation, as evidenced by the limited number of active matters.
The prosecution of this portfolio is highly centralized, involving 1 distinct examiner and 1 distinct art unit. This means that the company's entire pending strategy is subject to the review of a single administrative entity at the USPTO. While this concentration allows for a very focused legal strategy, it also means that the company's success is tied to the specific technical standards of that 1 distinct art unit.
PIHONAK, SARAH is the busiest examiner for the portfolio, currently handling 1 pending office action. As the only examiner involved, their individual assessment of the company's claims will be the deciding factor in the outcome of the current prosecution. Practitioners should closely study the past decisions of this official to effectively navigate the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PIHONAK, SARAH | 1 | 61.4% | +42.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18629463 | Anticonvulsant Compounds | PIHONAK, SARAH | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18629463 | Anticonvulsant Compounds | PIHONAK, SARAH | 1627 | §102§112DP | Final Rejection | — | Pending | Apr 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOwen-Barry Pharmaceuticals Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Sarah Pihonak has the most, with 1 of Owen-Barry Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.